Waters Corporation news

Waters Corporation (NYSE: WAT) today announced that the Waters® ACQUITY UPLC® I-Class IVD/Xevo® TQ-S micro IVD System is now manufactured as a U.S. FDA Class I medical device and is CE Marked to the European Directive 98/79/EC (IVDD). This development allows clinical laboratories to access leading innovations in liquid chromatography (LC) and mass spectrometry (MS) technology for the analysis of a variety of compounds that include diagnostic indicators in laboratory-de

Waters Corporation (WAT:NYSE) today introduced the first-of-its-kind Waters ACQUITY UPLC H-Class Bio System, expanding the scientific and business benefits of UPLC Technology for macromolecule analysis by optimizing characterization of biomolecule structures supporting their progression to viable biotherapeutics.

`By nature of their complexity, large biomolecules present significant analytical challenges that have been uniquely addressed by the new ACQUITY UPLC H-Class Bio System,` sa

Waters Corporation (WAT:NYSE) and Ireland’s National Institute for Bioprocessing Research and Training (NIBRT) announced today a collaboration that will create the world’s first database for glycan analysis by UltraPerformance Liquid Chromatography (UPLC). Expected to be available in 2011, NIBRT will develop, maintain and license the database while Waters and NIBRT will co-market it worldwide.

Manufacturing biomolecules can be notoriously difficult. Correct glycosylation i

Waters Corporation (WAT:NYSE) today introduced the first UltraPerformance LC (UPLC) analytical size-exclusion chromatography (SEC) solution for the characterization of proteins and their aggregates. The UPLC solution combines the first commercial sub two micron particle for SEC applications – the new patent–pending ACQUITY UPLC BEH200, 1.7µm SEC Columns - with the Waters ACQUITY UPLC System to give manufacturers the ability to separate and quantify monoclonal antibodies (mAb